Protection against nephropathy in diabetes with atorvastatin

Trial Profile

Protection against nephropathy in diabetes with atorvastatin

Completed
Phase of Trial: Phase III

Latest Information Update: 29 Jan 2015

At a glance

  • Drugs Atorvastatin (Primary)
  • Indications Diabetic nephropathies; Proteinuria
  • Focus Pharmacodynamics; Therapeutic Use
  • Acronyms PANDA
  • Most Recent Events

    • 19 Mar 2014 Accrual to date is 98% according to United Kingdom Clinical Research Network record.
    • 17 Aug 2013 Accrual to date is 98% according to United Kingdom Clinical Research Network record.
    • 15 Mar 2011 Status changed from active, no longer recruiting to completed.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top